カテゴリ： GlobalData, アメリカ, 企業調査

Advaxis Inc (ADXS)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Advaxis Inc (ADXS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C10001
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：89
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Advaxis Inc (Advaxis) is a biotechnology company that focuses on the discovery, development and commercialization of multiple cancer immunotherapies. The company develops immunotherapies based on its proprietary Lm Technology that uses bioengineered live attenuated Listeria monocytogenes (Lm) bacteria to stimulate cancer-fighting T cells directed against a cancer antigen, and lessen factors that protect the tumor microenvironment from immunologic attack and contribute to tumor growth. Under the Lm Technology platform, the company has four immunotherapy candidates in development, Axalimogene filolisbac (AXAL) in Human Papilloma Virus (HPV)-associated cancers; Neoantigen Therapy (ADXS-NEO); ADXS-PSA in prostate cancer; and ADXS-HER2 in HER2-expressing solid tumors. Advaxis is headquartered in Princeton, New Jersey, the US.

Advaxis Inc (ADXS) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Advaxis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Advaxis Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Advaxis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Advaxis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Advaxis Inc, Medical Devices Deals, 2012 to YTD 2018 10
Advaxis Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Advaxis Inc, Pharmaceuticals & Healthcare, Deal Details 13
Partnerships 13
Advaxis and Bristol-Myers Squibb Enter into Agreement 13
Amgen Forms Partnership with Advaxis 14
Advaxis Enters into Co-Development Agreement with Especificos Stendhal 15
Advaxis Enters into Research Agreement with Memorial Sloan Kettering Cancer Center 16
Advaxis Enters into Research Agreement with Sorrento Therapeutics 17
Advaxis Enters into Agreement with Merck 18
Advaxis Enters into Agreement with MedImmune 19
Licensing Agreements 20
OS Therapies Enters into Licensing Agreement with Advaxis 20
Sellas Life Sciences Enters into Licensing Agreement with Advaxis 21
Knight Therapeutics Enters into Licensing Agreement with Advaxis 22
Advaxis and University of Pennsylvania Restructure Their Exclusive License Agreement 23
Aratana Therapeutics Enters into Licensing Agreement with Advaxis 24
Advaxis Enters Into Licensing Agreement With Biocon For ADXS-HPV 26
Advaxis Enters Into Licensing Agreement With Global BioPharma For ADXS-HPV 28
Advaxis Enters Into Agreement With FusionVax To License ADXS-HPV In Asia 30
Equity Offering 31
Advaxis Raises USD20 Million in Public Offering of Shares and Warrants 31
Advaxis Plans to Raise up to USD250 in Public Offering of Securities 33
Advaxis Prices Public Offering of Shares for USD20 Million 34
Advaxis Raises USD30.3 Million in Private Placement of Shares 36
Advaxis Raises USD25 Million in Private Placement of Shares 37
Advaxis Raises USD61.2 Million in Public Offering of Shares 39
Advaxis Raises USD23 Million in Private Placement of Common Stock 41
Advaxis Raises USD17 Million in Private Placement of Shares 43
Advaxis Raises USD14 Million in Public Offering Of Shares 45
Advaxis Completes Public Offering Of Shares For US$26.5 Million 46
Advaxis Announces Private Placement Of Common Stock For US$10 Million 47
Advaxis Inc – Key Competitors 48
Advaxis Inc – Key Employees 49
Advaxis Inc – Locations And Subsidiaries 50
Head Office 50
Recent Developments 51
Financial Announcements 51
Sep 10, 2018: Advaxis reports fiscal 2018 third quarter financial results 51
Jun 07, 2018: Advaxis Announces Prioritization of Product Portfolio and Reports Fiscal 2018 Second Quarter Financial Results 53
Mar 12, 2018: Advaxis Announces Q1 Fiscal 2018 Financial Results 55
Dec 20, 2017: Advaxis Reports Fiscal Year 2017 Financial Results and Provides a Business Update 57
Sep 11, 2017: Advaxis Reports Business Update and Third Quarter 2017 Results 59
Corporate Communications 61
Jun 06, 2018: Advaxis Appoints Molly Henderson as Chief Financial Officer 61
Jul 06, 2017: Advaxis Announces Change in Leadership 62
Apr 19, 2017: Advaxis Appoints Anthony Lombardo as Chief Business Officer 63
Product News 64
Jun 01, 2017: Synthetic Genomics Launches cGMP Suite for Pharmaceutical Quality Manufacturing of Synthetic DNA for Advaxis’ Clinical Trials 64
03/26/2018: Advaxis Announces Four Poster Presentations Highlighting Lm-based Antigen Delivery Technology at AACR 2018 65
03/12/2018: Advaxis Announces Clinical Hold in Axalimogene Filolisbac Phase 1/2 Combination Study with AstraZeneca’s IMFINZI (Durvalumab) 66
01/29/2018: Data Highlighting Advaxis Antigen Delivery Platform Accepted for Multiple Presentations at 2018 Keystone Symposia Conference on Cancer Immunotherapies 67
01/25/2017: New Published Research Reveals that Cervical Cancer Mortality Rates May Be Significantly Higher in the United States than Previously Reported 68
Product Approvals 69
Jul 13, 2018: Advaxis Announces FDA Lifts Clinical Hold on Phase 1/2 Combination Study of Axalimogene Filolisbac with Durvalumab 69
Feb 13, 2018: Advaxis Submits Conditional Marketing Authorization Application for Axalimogene Filolisbac for the Second-Line Treatment of Metastatic Cervical Cancer in European Union 70
Mar 23, 2017: EMA Certification Paves the Way for the MAA Submission for Axalimogene Filolisbac in Metastatic Cervical Cancer 71
Clinical Trials 72
Apr 17, 2018: Preclinical Data Highlighting ADXS-Hot as Immunotherapy with Potential to Target Hotspot Cancer Mutations across Multiple Cancer Types Presented in Poster Discussion at The AACR Annual Meeting 72
Feb 12, 2018: Advaxis Announces Publication Of Phase 2 Results Evaluating Axalimogene Filolisbac For The Treatment Of Recurrent Metastatic Cervical Cancer In The International Journal Of Gynecological Cancer 73
Jul 13, 2017: Advaxis Lead Immunotherapy Candidate Continues to Build Recognition Among Industry Leaders 74
Jun 26, 2017: Advaxis Axalimogene Filolisbac Data Selected for Poster Presentation at ESGO 2017 75
May 18, 2017: Advaxis to Host Investor & Analyst Day on June 12 76
Mar 27, 2017: Advaxis Provides Phase 1 Data of Higher Dose Axalimogene Filolisbac 77
Mar 15, 2017: Advaxis Presents Oral Late-breaking Data on Phase 2 GOG-0265 Study of Axalimogene Filolisbac at SGO’s Annual Meeting on Women’s Cancer 78
Feb 06, 2017: Advaxis Announces First Patient Dosed in Global Phase 3 AIM2CERV Trial for High-risk, Locally Advanced Cervical Cancer 80
Jan 30, 2017: GOG-0265 Study in Metastatic Cervical Cancer Selected for Late-Breaking Data Presentation at the Society of Gynecologic Oncology’s Annual Meeting on Women’s Cancer 81
Other Significant Developments 82
Jul 10, 2018: Advaxis Provides Update on MAA Filing and ADXS-HOT Program 82
Jun 13, 2017: Advaxis Details Registrational Trials, EU Regulatory and Commercial Plans at Annual Investor & Analyst Day 83
Jan 09, 2017: Advaxis Provides 2017 Business Outlook 86
Appendix 89
Methodology 89
About GlobalData 89
Contact Us 89
Disclaimer 89

List of Tables
Advaxis Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Advaxis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Advaxis Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Advaxis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Advaxis Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Advaxis Inc, Medical Devices Deals, 2012 to YTD 2018 10
Advaxis Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Advaxis and Bristol-Myers Squibb Enter into Agreement 13
Amgen Forms Partnership with Advaxis 14
Advaxis Enters into Co-Development Agreement with Especificos Stendhal 15
Advaxis Enters into Research Agreement with Memorial Sloan Kettering Cancer Center 16
Advaxis Enters into Research Agreement with Sorrento Therapeutics 17
Advaxis Enters into Agreement with Merck 18
Advaxis Enters into Agreement with MedImmune 19
OS Therapies Enters into Licensing Agreement with Advaxis 20
Sellas Life Sciences Enters into Licensing Agreement with Advaxis 21
Knight Therapeutics Enters into Licensing Agreement with Advaxis 22
Advaxis and University of Pennsylvania Restructure Their Exclusive License Agreement 23
Aratana Therapeutics Enters into Licensing Agreement with Advaxis 24
Advaxis Enters Into Licensing Agreement With Biocon For ADXS-HPV 26
Advaxis Enters Into Licensing Agreement With Global BioPharma For ADXS-HPV 28
Advaxis Enters Into Agreement With FusionVax To License ADXS-HPV In Asia 30
Advaxis Raises USD20 Million in Public Offering of Shares and Warrants 31
Advaxis Plans to Raise up to USD250 in Public Offering of Securities 33
Advaxis Prices Public Offering of Shares for USD20 Million 34
Advaxis Raises USD30.3 Million in Private Placement of Shares 36
Advaxis Raises USD25 Million in Private Placement of Shares 37
Advaxis Raises USD61.2 Million in Public Offering of Shares 39
Advaxis Raises USD23 Million in Private Placement of Common Stock 41
Advaxis Raises USD17 Million in Private Placement of Shares 43
Advaxis Raises USD14 Million in Public Offering Of Shares 45
Advaxis Completes Public Offering Of Shares For US$26.5 Million 46
Advaxis Announces Private Placement Of Common Stock For US$10 Million 47
Advaxis Inc, Key Competitors 48
Advaxis Inc, Key Employees 49

List of Figures
Advaxis Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Advaxis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Advaxis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Advaxis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Advaxis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Advaxis Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Advaxis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Advaxis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Advaxis Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Advaxis Inc (ADXS)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Mylan NV (MYL)-医療機器分野：企業M&A・提携分析
    Summary Mylan NV (Mylan) is a pharmaceutical company, which develops, licenses, manufactures, markets and distributes generics and branded medicines and consumer healthcare products. It offers pharmaceutical products in multiple forms across therapeutic categories such as respiratory and allergy, ca …
  • Ad Scientiam：企業の製品パイプライン分析
    Summary Ad Scientiam is a medical technology company that offers digital biomarkers which collects physiological and behavioral data. It provides mobile application which monitors patients’ behaviors and sharers the data to healthcare professionals. Ad Scientiam serves individuals, healthcare profes …
  • Ghent University-製薬・医療分野：企業M&A・提携分析
    Summary Ghent University (Ghent) is an educational institution that provides research-based educational programmes and services. The university provides educational services such as international courses, preparatory language courses, programmes for exchange students and language courses, among othe …
  • Mercuria Energy Group Ltd：企業の戦略的SWOT分析
    Mercuria Energy Group Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Ahli Bank Qsc：企業の戦略・SWOT・財務分析
    Ahli Bank Qsc - Strategy, SWOT and Corporate Finance Report Summary Ahli Bank Qsc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Rockwell Medical Inc (RMTI)：医療機器：M&Aディール及び事業提携情報
    Summary Rockwell Medical Inc (Rockwell) is a biopharmaceutical company that focuses on the development, manufacture and distribution of products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The company’s major products include Triferic, an iron d …
  • Geron Corp (GERN)：医療機器：M&Aディール及び事業提携情報
    Summary Geron Corp (Geron) is a clinical stage biopharmaceutical company, which develops a telomerase inhibitor as a potential treatment for cancer. The company is evaluating its flagship product candidate Imetelstat in two clinical trials: IMbark and IMerge in partnership with Janssen Biotech, Inc. …
  • University of Aberdeen-製薬・医療分野：企業M&A・提携分析
    Summary University of Aberdeen (UOA) is an educational and research institution that offers undergraduate, graduate, postgraduate and research programs in a range of subjects. The university offers undergraduate and postgraduate courses in the areas of arts, creative arts, commerce, education, engin …
  • Holloway Lodging Corporation：戦略・SWOT・企業財務分析
    Holloway Lodging Corporation - Strategy, SWOT and Corporate Finance Report Summary Holloway Lodging Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Cutispharma Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary CutisPharma Inc (CutisPharma) is a pharmaceutical company that develops and distributes kits. The company offers products such as oral suspensions, suppositories, oral solutions, and topical, among others. Its oral solutions and oral suspensions include mouthwashes, anti-microbial, and PPIs; …
  • ADMA Biologics Inc (ADMA)：製薬・医療：M&Aディール及び事業提携情報
    Summary ADMA Biologics Inc (ADMA Biologics) is an integrated biopharmaceutical and specialty immunoglobulin company that develops, produces, and commercializes specialty biologics to treat immune deficiencies and prevent certain infectious diseases. The company develops RI-002, is a specialty plasma …
  • Jiangsu Hengrui Medicine Co Ltd (600276)：製薬・医療：M&Aディール及び事業提携情報
    Summary Jiangsu Hengrui Medicine Co Ltd (Jiangsu Hengrui) is a biopharmaceutical company that focuses on the research, development, manufacture and distribution of novel pharmaceutical products. Its product portfolio includes antineoplastic products, anti-tumor drugs, surgical drugs and contrast age …
  • MindTree Ltd.：企業の戦略・SWOT・財務情報
    MindTree Ltd. - Strategy, SWOT and Corporate Finance Report Summary MindTree Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Exploration and Production KazMunaiGas (KMG)：石油・ガス：M&Aディール及び事業提携情報
    Summary Exploration and Production KazMunaiGas (KMG EP), a subsidiary of National Company KazMunaiGas, is an upstream oil and gas company. The company carries out the exploration, development, production, processing and export of hydrocarbons and acquisition of oil and gas assets in Kazakhstan. Its …
  • Tompkins Financial Corp (TMP)：企業の財務・戦略的SWOT分析
    Tompkins Financial Corp (TMP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Hikal Ltd (HIKAL)：企業の財務・戦略的SWOT分析
    Summary Hikal Ltd (Hikal) is a pharmaceutical company that provides custom manufacturing; active ingredients and intermediates. The company provides product portfolio such as antiepileptic, antihistamine, antipsychotic and antilipemic, among others. It offers services such as custom synthesis, contr …
  • Plasticell Ltd：製薬・医療：M&Aディール及び事業提携情報
    Summary Plasticell Ltd (Plasticell) is a biotechnology company that develops therapies derived from research using its combinatorial cell culture technology. The company offers therapeutic programs such as expansion of hematopoietic stem cells from bone marrow and cord blood, platelets and immune ce …
  • NIBC Bank NV：電力：M&Aディール及び事業提携情報
    Summary NIBC Bank NV (NIBC), a subsidiary of NIBC Holding NV, is an enterprising bank that provides a range of corporate and consumer banking services. The company specializes in mergers and acquisitions, debt and equity mezzanine, capitalization advisory, leveraged finance and structured finance, a …
  • Ford Motor Company：企業の戦略・SWOT・財務情報
    Ford Motor Company - Strategy, SWOT and Corporate Finance Report Summary Ford Motor Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • amcure GmbH-製薬・医療分野：企業M&A・提携分析
    Summary amcure GmbH (Amcure) is biopharmaceutical company which discovers and develops therapeutics for the treatment of cancer. It develops peptide-based compounds for the treatment of metastatic forms of cancer. The company’s lead candidate AMC303, is in Phase I clinical trial and used for the tre …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆